



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2020

---

## **Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice**

Caduff, Nicole ; McHugh, Donal ; Murer, Anita ; Rämer, Patrick ; Raykova, Ana ; Landtwing, Vanessa ;  
Rieble, Lisa ; Keller, Christian W ; Prummer, Michael ; Hoffmann, Laurent ; Lam, Janice K P ; Chiang,  
Alan K S ; Raulf, Friedrich ; Azzi, Tarik ; Berger, Christoph ; Rubic-Schneider, Tina ; Traggiai,  
Elisabetta ; Lünemann, Jan D ; Kammüller, Michael ; Münz, Christian

Abstract: [This corrects the article DOI: 10.1371/journal.ppat.1008477].

DOI: <https://doi.org/10.1371/journal.ppat.1009167>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-197190>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Caduff, Nicole; McHugh, Donal; Murer, Anita; Rämer, Patrick; Raykova, Ana; Landtwing, Vanessa;  
Rieble, Lisa; Keller, Christian W; Prummer, Michael; Hoffmann, Laurent; Lam, Janice K P; Chiang,  
Alan K S; Raulf, Friedrich; Azzi, Tarik; Berger, Christoph; Rubic-Schneider, Tina; Traggiai, Elisabetta;  
Lünemann, Jan D; Kammüller, Michael; Münz, Christian (2020). Correction: Immunosuppressive FK506  
treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. *PLoS  
Pathogens*, 16(12):e1009167.

DOI: <https://doi.org/10.1371/journal.ppat.1009167>

CORRECTION


# Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

Nicole Caduff, Donal McHugh, Anita Murer, Patrick Rämer, Ana Raykova, Vanessa Landtwing, Lisa Rieble, Christian W. Keller, Michael Prummer, Laurent Hoffmann, Janice K. P. Lam, Alan K. S. Chiang, Friedrich Raulf, Tarik Azzi, Christoph Berger, Tina Rubic-Schneider, Elisabetta Traggiai, Jan D. Lünemann, Michael Kammüller, Christian Münz

The following information is missing from the Funding statement: AKSC was supported by a HMRF grant (18170462).

## Reference

1. Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, et al. (2020) Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 16(4): e1008477. <https://doi.org/10.1371/journal.ppat.1008477> PMID: 32251475



## OPEN ACCESS

**Citation:** Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, et al. (2020) Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 16(12): e1009167. <https://doi.org/10.1371/journal.ppat.1009167>

**Published:** December 21, 2020

**Copyright:** © 2020 Caduff et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.